Ikarian Capital’s Cymabay Therapeutics CBAY Stock Holding History

Ikarian Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-104,300	Closed	-$1.56M	–	188
2023 Q3	$1.56M	Buy	+104,300	New	+$1.38M	0.19%	86
2020 Q3	–	Sell	-1,529,830	Closed	-$5.34M	–	216
2020 Q2	$5.34M	Sell	1,529,830 -837,020	-35%	-$2.42M	0.42%	63
2020 Q1	$3.5M	Buy	+2,366,850	New	+$3.97M	0.26%	76

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ikarian Capital's CBAY Position: Q4 2023 in Review

Ikarian Capital sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 104,300 shares — an estimated $1.56M sold.

Ikarian Capital first reported a position in CBAY in Q1 2020 and held it in 3 quarters. The position peaked at $5.34M in Q2 2020. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Ikarian Capital reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Ikarian Capital sold 104,300 Cymabay Therapeutics shares in Q4 2023, an estimated $1.56M.
Ikarian Capital first reported a position in Cymabay Therapeutics in Q1 2020 and held it in 3 quarters.
Ikarian Capital's Cymabay Therapeutics position peaked at $5.34M in Q2 2020.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.